×

Intercept to Report First Quarter 2015 Financial Results on May 11 and Present at Upcoming Conferences

NEW YORK, May 4, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced that it will report first quarter 2015 financial results before the NASDAQ Market opens on Monday, May 11, 2015. Intercept management will conduct a conference call and audio webcast on Monday, May 11, 2015 at 9:45 a.m. ET to discuss these results.

Intercept management will also be presenting at the following investor conferences:

- Bank of America Merrill Lynch 2015 Health Care Conference on May 12, 2015 at 3:40 p.m. Pacific Time

- UBS Global Healthcare Conference on May 19, 2015 at 4:00 p.m. Eastern Time

- Goldman Sachs Global Healthcare Conference on June 10, 2015 at 3:20 p.m. Pacific Time

Date: May 11, 2015 Time: 9:45 AM ET Listen via Internet: http://ir.interceptpharma.com/ Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=68598&k=472888D9 Telephone: (315) 625-6894 Toll-free: (855) 232-3919 Access code: not required

Dial-in and webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases. The company's lead product candidate, obeticholic acid (OCA), is an agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases, including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. The FDA has granted OCA breakthrough therapy designation for the treatment of NASH with fibrosis, a population representing potentially more than 14 million patients in the United States, and granted OCA fast track designation for the treatment of patients with PBC who have an inadequate response to or are intolerant of ursodiol. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.

CONTACT: For more information about Intercept, please contact Barbara Duncan or Senthil Sundaram, both of Intercept Pharmaceuticals at 1-646-747-1000. Media inquiries: media@interceptpharma.com Investor inquiries: investors@interceptpharma.com Source:Intercept Pharmaceuticals, Inc.